Show simple item record

dc.contributor.authorSackeim, Harold A.
dc.contributor.authorAaronson, Scott T.
dc.contributor.authorBunker, Mark T.
dc.creatorSackeim, H.
dc.date.accessioned2019-04-19T12:34:44Z
dc.date.available2019-04-19T12:34:44Z
dc.date.issued2019-03-21
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063949695&origin=inward
dc.identifier.urihttp://hdl.handle.net/10713/8859
dc.description.abstractThere is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes (e.g., pharmacotherapy, brain stimulation, and psychotherapy), the subgroups of patients for whom distinct adequacy criteria are needed (e.g., bipolar vs. unipolar depression, psychotic vs. nonpsychotic depression), whether trials should be rated dichotomously as adequate or inadequate or on a potency continuum, whether combination and augmentation strategies require specific consideration, and the criteria used to evaluate the adequacy of treatment delivery (e.g., dose, duration), trial adherence, and clinical outcome. This review also presents the Antidepressant Treatment History Form: Short-Form (ATHF-SF), a completely revised version of an earlier instrument, and details how these fundamental issues were addressed in the ATHF-SF. © 2019 The Authorsen_US
dc.description.sponsorshipLivaNova. Agency for Healthcare Research and Quality. Takeda Oncology. Foundation for Barnes-Jewish Hospital. Pfizer. Stanley Medical Research Institute. Forest Laboratories. ACADIA Pharmaceuticals. Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis. Johnson and Johnson. National Institute of Mental Health. Bristol-Myers Squibb
dc.description.urihttps://doi.org/10.1016/j.jpsychires.2019.03.021en_US
dc.language.isoen_USen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofJournal of Psychiatric Researchen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectAntidepressant treatment resistanceen_US
dc.subjectBrain stimulationen_US
dc.subjectMajor depressive episodeen_US
dc.subjectPharmacotherapyen_US
dc.subjectPsychotherapyen_US
dc.subjectTreatment-resistant depressionen_US
dc.titleThe assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF)en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jpsychires.2019.03.021
dc.relation.volume113


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States